Status:
COMPLETED
Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients
Lead Sponsor:
National Heart Institute, Mexico
Conditions:
Contrast Induced Nephropathy
Acute Renal Failure
Eligibility:
All Genders
20-85 years
Brief Summary
Hypothesis: Cystatin C compared with creatinine is a better and earlier marker of contrast-induced nephropathy in high and intermedium risk cardiac catheterization patients. Primary Objective: Esta...
Detailed Description
Contrast induced-nephropathy is a complication that is underestimated in clinical practice after cardiac catheterization. During the last 30 years, because of the increasing use of contrast medium for...
Eligibility Criteria
Inclusion
- Age over 20 years old
- Indication for coronariography and/or percutaneous coronary intervention
- Voluntary written consent for the realization of coronariography and/or percutaneous intervention and for the participation in this clinical trial
- A MEHRAN contrast-induced nephropathy score from six to fifteen.
Exclusion
- N-Acetylcystein and Fenoldopam pre-medication
- Low risk patients according MEHRAN classification
- Cardiogenic and septic shock
- Acute renal failure by any other cause
- Patients with chronic kidney failure requiring any kind of dialysis
- Patients unable to complete follow-up
- Exposure to contrast media 48 hours prior to study
- Patients unable to give consent
- Receiving contrast media other than non-ionic
Key Trial Info
Start Date :
December 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2008
Estimated Enrollment :
66 Patients enrolled
Trial Details
Trial ID
NCT00467311
Start Date
December 1 2006
End Date
April 1 2008
Last Update
May 8 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ignacio Chávez National Institute of Cardiology
Mexico City, Mexico City, Mexico, 01480